Clinical Trial Details
— Status: Active, not recruiting
Administrative data
NCT number |
NCT05886309 |
Other study ID # |
2023-00550; th22Infanti |
Secondary ID |
|
Status |
Active, not recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
February 12, 2024 |
Est. completion date |
June 2024 |
Study information
Verified date |
March 2024 |
Source |
University Hospital, Basel, Switzerland |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
The study will explore the performance of the CDMS (Cryo Detector Mass Spectrometer) method
in measuring SF (serum ferritin) in human serum of healthy individuals. This will be the
first experience of testing SF with this method using biologic material of human origin.
Description:
A clear interpretation of hyperferritinemia is difficult in many clinical situations. Crucial
for the correct treatment of patients is the differentiation between reactively elevated
ferritin and effective iron overload.The measurement methods that are routinely used provide
quantitative results of the measurement of total ferritin molecules independent of their
actual iron content.With a modified mass spectrometric method (CDMS), this should be
possible.
In this study the investigators would like to apply this measurement technique for the first
time with human serum as the investigators would like to test healthy blood donors with known
normal, low or elevated ferritin levels.